Phase III Study of Cadonilimab with Chemotherapy Followed by Chemoradiotherapy for Treating Locally Advanced Cervical Cancer in Women Aged 18 to 70

What this Trial Is About

Researchers are evaluating the effectiveness and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy compared to the standard concurrent chemoradiotherapy for treating locally advanced cervical cancer. This Phase III, multicenter, open-label randomized controlled study aims to improve treatment options for patients with this condition. The study includes three groups one receiving standard concurrent chemoradiotherapy another undergoing immune induction chemotherapy combined with reduced-dose radiotherapy and reduced-dose concurrent chemotherapy followed by immune maintenance therapy and a third group receiving immune induction chemotherapy combined with reduced-dose radiotherapy followed by immune maintenance therapy after completing radiotherapy and chemotherapy. Treatments involve radiation therapy, chemotherapy drugs such as cisplatin and albumin paclitaxel, and the immunotherapy drug Cadonilimab administered in various dosing schedules. Participants will be monitored over time for progression-free survival using RECIST 1.1 criteria, with follow-up lasting up to approximately 55 months. Researchers will also assess objective response rates, overall survival, duration and time to response, and disease control rates. Safety and treatment effects will be evaluated through clinical assessments, imaging, and laboratory tests during regular study visits throughout the trial period.

A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT